JP4070935B2 - Acne skin external preparation - Google Patents
Acne skin external preparation Download PDFInfo
- Publication number
- JP4070935B2 JP4070935B2 JP2000098285A JP2000098285A JP4070935B2 JP 4070935 B2 JP4070935 B2 JP 4070935B2 JP 2000098285 A JP2000098285 A JP 2000098285A JP 2000098285 A JP2000098285 A JP 2000098285A JP 4070935 B2 JP4070935 B2 JP 4070935B2
- Authority
- JP
- Japan
- Prior art keywords
- acne
- singlet oxygen
- skin
- extract
- external preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims description 61
- 206010000496 acne Diseases 0.000 title claims description 61
- 238000002360 preparation method Methods 0.000 title claims description 40
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 60
- 230000002000 scavenging effect Effects 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 8
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 2
- 235000013793 astaxanthin Nutrition 0.000 claims description 2
- 229940022405 astaxanthin Drugs 0.000 claims description 2
- 239000001168 astaxanthin Substances 0.000 claims description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960002591 hydroxyproline Drugs 0.000 claims description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 50
- 239000000284 extract Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 229940123973 Oxygen scavenger Drugs 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 21
- 239000002260 anti-inflammatory agent Substances 0.000 description 14
- 229940121363 anti-inflammatory agent Drugs 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 239000012190 activator Substances 0.000 description 12
- 230000002265 prevention Effects 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 239000003899 bactericide agent Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 150000004032 porphyrins Chemical class 0.000 description 7
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 6
- 239000007844 bleaching agent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000002087 whitening effect Effects 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- -1 packs Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940031439 squalene Drugs 0.000 description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229960003720 enoxolone Drugs 0.000 description 3
- 239000000417 fungicide Substances 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 239000000453 juniperus communis l. leaf oil Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000010330 ougon Substances 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、にきび用皮膚外用剤に関し、更に詳細には、一定以上の一重項酸素消去能力を奏する量の一重項酸素消去剤を含有することにより、にきびの予防や改善に有効なにきび用皮膚外用剤に関する。
【0002】
【従来の技術】
にきびは、尋常性座瘡とも呼ばれ、毛孔に一致して丘疹あるいは膿疱の生じる現象をいう。にきびは、特に思春期、青年期の男女の、顔面等に生じるものであるため、その予防や改善が強く求められている。このため、にきびを予防、改善するための皮膚外用剤、例えば、乳液、クリーム、化粧水、パック、洗浄料、分散液、軟膏、外用液剤等が数多く提供されている。
【0003】
これらの皮膚外用剤には、にきびを予防または改善するための成分として、従来からグリチリチン酸やグリチルレチン酸及びそれらの誘導体などの抗炎症剤やイオウ、レゾルシンなどの殺菌剤が用いられてきた。
【0004】
【発明が解決しようとする課題】
しかしながら、これらの抗炎症剤や殺菌剤は、にきびの予防や改善効果が十分でなかったり、あるいは、製剤中で変質するなどして所期の薬効が得られない場合が多かった。従って、にきびの予防や改善効果が優れた薬剤を見出し、これを配合したにきび用皮膚外用剤の提供が望まれていた。
【0005】
【課題を解決するための手段】
本発明者らは、にきびに関連する因子を種々探求していたところ、にきびの発症に一重項酸素が大きく関与していることを突き止めた。そして、皮膚外用剤に所定以上の一重項酸素消去能力となる量の一重項酸素消去剤を配合すれば、にきび予防及び改善効果を著しく向上させることができることおよび、更にこの一重項酸素消去剤に紫外線防止剤や美白剤、抗炎症剤、殺菌剤、細胞賦活剤等の薬剤を組み合わせれば、より高いにきび予防及び改善効果が得られることを見出し本発明を完成した。
【0006】
すなわち本発明は、一重項酸素消去能力として50s−1以上となる量の一重項酸素消去剤を含有することを特徴とするにきび用皮膚外用剤を提供するものである。
【0007】
また本発明は、次の成分(A)及び(B)
(A)一重項酸素消去能力として50s−1以上となる量の一重項酸素消去剤
(B)紫外線防止剤の一種又は二種以上
を含有することを特徴とするにきび用皮膚外用剤を提供するものである。
【0008】
更に本発明は、上記にきび用皮膚外用剤に成分(C)
(C)美白剤、抗炎症剤、殺菌剤および細胞賦活剤から選ばれる薬剤の一種又は二種以上
を含有するにきび用皮膚外用剤を提供するものである。
【0009】
【発明の実施の形態】
本発明において用いられる一重項酸素消去剤としては、一重項酸素を有効に消去することができ、皮膚外用剤に添加した場合に特段の問題を生じない化合物を含むものであれば特に限定なく使用することができる。この一重項酸素消去剤として作用する化合物は、どのような測定方法によってスクリーニングしてもよいが、例えば一重項酸素検出装置(特開平7−159325号)を用いることにより、容易にスクリーニングすることができる。
【0010】
本発明において、一重項酸素消去剤の有効成分として利用される化合物の具体例としては、ルチンおよびその誘導体、クエルセチン、β−カロチン、アスタキサンチン、ゼアキサンチン、ビタミンE及びその誘導体並びにそれらの塩、エリソルビン酸、ヒスチジン、トリプトファン、チロシン、メチオニン、シスチン、ヒポタウリン、チオタウリン、ニンジン抽出物、マイカイカ抽出物、サンペンズ抽出物、メリッサ抽出物、ヤシャジツ抽出物、羅漢果抽出物、茶抽出物、リン脂質等が挙げられる。
【0011】
本発明のにきび用皮膚外用剤における、一重項酸素消去剤の含有量は、その一重項酸素消去能力として50s−1以上となる量であることが必要である。すなわち、一重項酸素消去剤の有効成分である化合物は、それぞれ重量またはモル当たりの反応速度定数が決まっているが、この反応速度定数と配合濃度をかけて得られる一重項酸素消去能力を50s−1以上にすることが重要である。特にこの値を1000s−1以上とすれば、より優れたにきび予防及び改善効果が得られる。
【0012】
上記の一重項酸素消去剤は、これをにきびの予防または改善成分とし、常法に従って通常の皮膚外用剤に使用される種々の形態の基剤に配合し、製剤化することによりにきび用皮膚外用剤を得ることができるが、更に紫外線防止剤や他の薬効成分と組み合わせることにより、より効果の優れたにきび用皮膚外用剤が得られる。
【0013】
本発明において、一重項酸素消去剤((A)成分)と組合せ使用される紫外線防止剤((B)成分)としては、パラメトキシケイ皮酸−2−エチルヘキシル、オキシベンゾン、4−tert−ブチル−4'−メトキシジベンゾイルメタン、酸化チタン、微粒子酸化チタン、酸化亜鉛等が挙げられる。これらの紫外線防止剤のうち、特に好ましいものとしては、パラメトキシケイ皮酸−2−エチルヘキシル、酸化チタン、微粒子酸化チタン、酸化亜鉛が挙げられる。
【0014】
一方、他の薬効成分((C)成分)としては、美白剤、抗炎症剤、殺菌剤、細胞賦活剤から選ばれるものであるが、具体的な薬効剤の例としては、それぞれ以下に示すものが挙げられる。
【0015】
( 美白剤 )
美白剤としては、ビタミンC及びその誘導体並びにそれらの塩、胎盤抽出物、甘草抽出物、ヨクイニン抽出物、オウゴン抽出物、海藻抽出物、ビャクレン抽出物、センプクカ抽出物、ブドウ抽出物、コムギ抽出物、トマト抽出物等が挙げられる。
【0016】
これらの美白剤のうち、特に好ましいものとしては、ビタミンC及びその誘導体並びにそれらの塩、胎盤抽出物が挙げられる。
【0017】
( 抗炎症剤 )
抗炎症剤としては、グリチルリチン酸、グリチルレチン酸及びそれらの誘導体並びにそれらの塩、アロエ抽出物、シソ抽出物、ヨモギ抽出物、カミツレ抽出物、コンフリー抽出物、ジユ抽出物、クレソン抽出物、オウバク抽出物等が挙げられる。
【0018】
これらの抗炎症剤のうち、特に好ましいものとしては、グリチルリチン酸、グリチルレチン酸及びそれらの誘導体並びにそれらの塩が挙げられる。
【0019】
( 殺菌剤 )
殺菌剤としてはイオウ、レゾルシン、サリチル酸、イソプロピルメチルフェノール、塩化ベンザルコニウム、ヒノキチオール、ドクダミ抽出物、クララ抽出物等が挙げられる。
【0020】
これらの殺菌剤のうち、特に好ましいものとしてはイオウ、サリチル酸、イソプロピルメチルフェノールが挙げられる。
【0021】
( 細胞賦活剤 )
細胞賦活剤としては、ビタミンA及びその誘導体、クエン酸、乳酸、酒石酸、リンゴ酸、グリコール酸、コハク酸、セリン、グルタミン酸、ヒドロキシプロリン、テアニン、ピロリドンカルボン酸、酵母、乳酸菌およびビフィズス菌の醗酵代謝物等が挙げられる。
【0022】
これらの細胞賦活剤のうち、特に好ましいものとしては、ビタミンA及びその誘導体、クエン酸、リンゴ酸、乳酸、セリン、ピロリドンカルボン酸が挙げられる。
【0023】
本発明の皮膚外用剤における上記(B)成分の紫外線防止剤および(C)成分の薬効剤の配合量は、それぞれの種類により相違するが、以下に示す範囲とすることが好ましい。この範囲であれば、(A)成分の一重項酸素消去剤と組み合わせた場合、製剤及び製剤中の(A)成分の一重項酸素消去剤の経時安定性に影響を及ぼすことがなく、より高いにきび予防及び改善効果を発揮させることができる。
【0024】
すなわち、本発明における(B)成分の配合量としては、好ましくは0.001〜20質量%(以下、単に「%」で示す)、より好ましくは0.01〜10%の範囲である。この範囲であればより優れた紫外線防止効果が発現し、かつ、優れたにきび予防及び改善効果を示す皮膚外用剤が得られる。
【0025】
一方、本発明の(C)成分のうち美白剤の配合量は、好ましくは0.00001〜10%であり、より好ましくは0.0001〜5%の範囲である。胎盤抽出物及び植物抽出物を抽出液のまま用いる場合は乾燥固形分としてこの範囲であれば問題ない。この範囲であればより優れたにきび予防及び改善効果を示す皮膚外用剤が得られる。
【0026】
また、本発明の(C)成分のうち抗炎症剤の配合量は、0.00001〜5%の範囲が好ましく、より好ましくは0.0001〜3%の範囲である。植物抽出物を抽出液のまま用いる場合は乾燥固形分としてこの範囲であれば問題ない。この範囲であれば優れた抗炎症効果がみられ、かつ、優れたにきび予防及び改善効果を示す皮膚外用剤が得られる。
【0027】
更に、本発明の(C)成分のうち殺菌剤の配合量は0.00001〜5%の範囲が好ましく、より好ましくは0.0001〜3%の範囲である。植物抽出物を抽出液のまま用いる場合は乾燥固形分としてこの範囲であれば問題ない。この範囲であれば優れた殺菌効果がみられ、かつ、優れたにきび予防及び改善効果を示す皮膚外用剤が得られる。
【0028】
更にまた、本発明の(C)成分である細胞賦活剤の配合量は、好ましくは0.00001〜5%、より好ましくは0.0001〜3%の範囲である。この範囲であればより優れた肌荒れ改善効果が発現し、かつ、優れたにきび予防及び改善効果を示す皮膚外用剤が得られる。
【0029】
本発明のにきび用皮膚外用剤の製造に当たっては、(B)成分である紫外線防止剤と(C)成分である薬効剤(美白剤、抗炎症剤、殺菌剤および細胞賦活剤)は、これらを組合せて使用することができ、また、それぞれの成分中で複数の化合物ないしは薬効剤を配合することもできる。更に、(C)成分の薬効剤である美白剤、抗炎症剤、殺菌剤および細胞賦活剤も、それぞれから複数の化合物を選択し、二種以上組み合わせて用いることもできる。
【0030】
本発明の成分(A)に、成分(B)および/または成分(C)を組み合わせた皮膚外用剤は、常法に従い、これら各成分を通常の皮膚外用剤として知られる種々の形態の基剤に配合して調製することができる。この場合における成分(A)の配合量も、前記したようにその一重項酸素消去能力として50s−1以上となる量であることが必要である。
【0031】
かくして得られるにきび用皮膚外用剤の配合形態は、特に限定されず、例えば、乳液、クリーム、化粧水、パック、洗浄料、メーキャップ化粧料、分散液、軟膏などの化粧料や外用医薬品等とすることができる。
【0032】
そして、上記皮膚外用剤の形態に応じ、前記必須成分以外に通常化粧品や医薬品等の皮膚外用剤に用いられる成分、例えば、精製水、低級アルコール、多価アルコール、油性成分、粉体、界面活性剤、増粘剤、色材、防腐剤、保湿剤、香料等を用いることができる。
【0033】
【作用】
本発明は、にきびの発症に一重項酸素が大きく関与しているという新規な知見に基づくものである。すなわち、皮脂を作り出す器官である皮脂腺には、アクネ菌(Propioniobacterium acnes)が棲息しており、アクネ菌は代謝産物としてポルフィリン類を産生し、菌体外に排出する。本発明者らの研究により、このポルフィリンは皮脂の分泌とともに皮膚表面に排出されることが明らかになった。そして、皮膚表面に排出されたポルフィリンに紫外線があたると、活性酸素の一種であり非常に反応性の高い一重項酸素が発生することを、我々の開発した一重項酸素検出装置(特開平7−159325号)を用いることにより直接検出した。
【0034】
また、皮膚表面にある表皮脂質が、意外にも紫外線照射のみでは全く過酸化されないのに対し、このポルフィリンの出す一重項酸素が存在することによってはじめて、しかも速やかに過酸化されることが明らかになった。そして、この過酸化脂質によって表皮の過角化が促進され、毛穴付近の角層が固く厚くなるため、毛穴が詰まりやすくなりにきびの原因となることをはじめて突き止めた。
【0035】
ところで、一重項酸素によって過酸化される表皮脂質成分の代表的なものがスクワレンであるから、にきびの原因となるスクワレンの過酸化を防ぐためには、スクワレンよりも一重項酸素と反応しやすい成分を皮膚に適用すればよい。そして、ある化合物の一重項酸素との反応のしやすさは反応速度定数と配合濃度によって決まるのであるから、両者を考慮して実際の皮膚外用剤中での一重項酸素消去能力が求められる。
【0036】
本発明はこのような知見を元に、一定数以上の一重項酸素消去能力を有する一重項酸素消去剤が皮膚上のスクワレンの過酸化を抑制し、にきびの予防及び改善に有効であるとして完成したものである。
【0037】
また、そもそも一重項酸素の発生源が紫外線によるポルフィリンの励起であることから、その原因である紫外線を防御することが、一重項酸素の障害の防御に有効であり、にきびの予防改善に非常に有効であることを見出したのである。
【0038】
【実施例】
次に実施例および試験例を挙げて本発明を更に詳細に説明するが、本発明はこれらになんら制約されるものではない。
【0039】
試 験 例 1
一重項酸素消去能力の測定:
特開平7−159325号に開示の一重項酸素検出装置を用い、表1に示す試験薬剤*について、下記のようにして一重項酸素消去速度定数を測定した。すなわち、対照試料としてローズベンガル100μM溶液を用い、これをフローセル中20mL/分の速度で循環させた。このセルにUVA波長のレーザー光を照射した。この照射により生ずる発光スペクトルは1268nmに一重項酸素由来のピークを有するので、この対照試料の発光強度をIoとする。次に対照試料中に試験薬剤を添加して同様の操作を行い、得られた発光強度をIsとした。試験薬剤の配合濃度(Cs)に対する発光強度の比Io/Isをプロットし、下のスターン・ボルマーの式(1)、
Io/Is = 1+kq・τ・Cs……(1)
τ : 一重項酸素の寿命(溶媒によって異なる定数)
Cs: 試験薬剤の配合濃度
により一重項酸素消去速度定数(kq)を求めた。
実際の一重項酸素消去能力は式(2)、
により、一重項酸素消去速度定数に実際の配合濃度をかけて求められる。なお、試験薬剤の濃度(Cs)は固形物濃度(g・L−1)で調製した。
【0040】
* 試験薬剤のうち、植物抽出物は次のようにして調製した。まず、各生薬を乾燥させ細切する。この細切した生薬10重量部に50%エチルアルコール水溶液100重量部を加え、室温にて時々攪拌しながら3日間抽出した後、濾過して各抽出物を得た。
【0041】
各試験薬剤の一重項酸素消去能力を評価した結果を、表1に示す。なお、一重項酸素消去能力は下記3段階に評価した。
【0042】
【0043】
( 結 果 )
【表1】
【0044】
表1の結果から明らかなごとく、A1〜A24の各試験薬剤は高い一重項酸素消去能力を有することが認められ、これらを配合した皮膚外用剤に、アクネ菌が産生するポルフィリンから発生する一重項酸素によるにきびの予防や改善効果があると判断された。
【0045】
実 施 例 1
乳 液:
以下に示す組成及び下記製法で乳液を調製し、にきび予防および改善効果を調べた。この結果を表2に示す。
【0046】
( 製 法 )
A. 成分(1)〜(6)を加熱混合し、70℃に保つ。
B. 成分(9)と(11)の一部を加熱混合し、70℃に保つ。
C. BにAを加えて混合し、均一に乳化する。
D. Cを冷却後(11)の残部に溶かした(7)、(8)、(12)および(10)に溶かした(13)を加え、均一に混合して乳液を得た。
【0047】
( 試験方法 )
被験乳液1品につき22歳から40歳の女性15名をパネルとし、毎日、朝と夜の2回、洗顔後に被験乳液の適量を顔面に塗布した。12週間塗布を行い、塗布によるにきび改善効果の有効性を、以下の3ランクで判断し、下記評価基準によって評価した。
【0048】
( 有効性ランク )
有 効 … … にきびが出来にくくなった。にきびが目立たなくなった。
やや有効 … … にきびがやや出来にくくなった。にきびがあまり目立たなくなった。
無 効 … … 使用前と変化なし。
【0049】
【0050】
( 結 果 )
【表2】
【0051】
表2に示される如く、表1で一重項酸素消去能力が50s−1以上になった一重項酸素消去剤を配合した皮膚外用剤は、これらを皮膚に適用することにより、にきびの防止、改善することができ、美しい肌とすることが明らかとなった。特に、好ましくは1000s−1以上になるように一重項酸素消去剤を配合した皮膚外用剤は、その効果が優れていた。
【0052】
実 施 例 2
乳 液 :
下記の基本組成に、表3で示す種類および量の一重項酸素消去剤や紫外線防止剤、美白剤、抗炎症剤、殺菌剤、細胞賦活剤などの薬剤を添加し、下記製法で乳液を調製して、美肌効果を調べた。この結果も表3に示す。なお、基本組成および表3に示された配合量は、最終製品である乳液での配合量である。
【0053】
【0054】
( 組成及び結果 )
【表3】
【0055】
( 製 法 )
A. 成分(1)〜(6)を加熱混合し、70℃に保つ。
B. 成分(9)と(11)の一部を加熱混合し、70℃に保つ。
C. BにAを加えて混合し、均一に乳化する。
D. Cを冷却後(11)の残部に溶かした(7)、(8)、(12)および表3の(13)〜(40)の成分を(10)に溶かして加え、均一に混合して乳液を得た。
【0056】
( 試験方法 )
被験乳液について、実施例1と同様にして評価した。
【0057】
表3の結果に示される如く、一重項酸素消去能力が50s−1以上となるよう一重項酸素消去剤を配合する皮膚外用剤は、これを紫外線防止剤や、美白剤、抗炎症剤、殺菌剤、細胞賦活剤と併用し、皮膚に適用することにより、一重項酸素消去剤を単独で配合した外用剤を適用した場合より更に優れたにきびの防止、改善効果を発揮し、透明感のある美しい肌とすることが明らかとなった。
【0058】
【0059】
( 製 法 )
A. 成分(3)、(4)、(9)及び(10)を混合溶解する。
B. 成分(1)、(2)、(5)〜(8)及び(11)を混合溶解する。
C. AとBを混合して均一にし、化粧水を得た。
【0060】
【0061】
( 製 法 )
A. 成分(1)〜(6)および(11)を混合し、加熱して70℃に保つ。
B. 成分(13)を加熱して70℃に保つ。
C. AにBを加え、(7)〜(10)及び(12)を混合した後、冷却してクリームを得た。
【0062】
実施例3で得た化粧水および実施例4で得たクリームは、いずれも経時安定性に優れ、皮膚に適用することにより、にきびを予防および改善し透明感のある美しい肌にするものであった。
【0063】
【0064】
( 製 法 )
A. 成分(3)、(4)及び(8)の一部を加熱混合し、75℃に保つ。
B. 成分(1)、(2)を加熱混合し、75℃に保つ。
C. AをBに徐々に加える。
D. Cを冷却しながら(8)の残部で溶解した(5)〜(7)を加え、軟膏 を得た。
【0065】
実施例5で得た軟膏は経時安定性に優れ、皮膚に適用することにより、にきびを防止し、透明感のある美しい肌にするものであった。
【0066】
【0067】
( 製 法 )
A. 成分(1)、(3)、(4)及び(10)を混合し、70℃に加熱し、撹拌する。
B. 成分(2)及び(8)を混合する。
C. 上記Bを先のAに加え、混合した後、冷却して(5)〜(7)及び(9)を均一に分散してパックを得た。
【0068】
実施例6のパックは経時安定性に優れ、皮膚に適用することにより、にきびを防止し、透明感のある美しい肌にするものであった。
【0069】
【0070】
( 製 法 )
A. 成分(1)〜(5)を混合溶解する。
B. Aに成分(10)〜(15)を加え、均一に混合し、70℃に保つ。
C. 成分(6)〜(9)を均一に溶解し、70℃に保つ。
D. BにCを添加して、均一に乳化する。
E. Dを冷却後、成分(16)〜(19)を添加してリキッドファンデーションを得た。
【0071】
実施例7で得られたリキッドファンデーションは経時安定性に優れ、皮膚に適用することにより、にきびを防止するものであった。
【0072】
【発明の効果】
以上のごとく、一定以上の一重項酸素消去能力を有する一重項酸素消去剤を含有する本発明の皮膚外用剤は、その一重項酸素消去能力によりアクネ菌の産生するポルフィリンから発生する一重項酸素を消去し、にきびの予防や改善に有効なものである。
【0073】
さらに、上記一重項酸素消去剤を紫外線吸収剤や、殺菌剤、抗炎症剤、美白剤、細胞賦活剤と組み合わせることにより、にきび対して高い予防効果及び改善効果を有すると共に、にきび跡の色素沈着改善等に有効な皮膚外用剤とすることができる。
以 上[0001]
BACKGROUND OF THE INVENTION
TECHNICAL FIELD The present invention relates to an external skin preparation for acne, and more specifically, skin for acne that is effective in preventing or improving acne by containing a singlet oxygen scavenger in an amount that exhibits a singlet oxygen scavenging ability above a certain level. It relates to an external preparation.
[0002]
[Prior art]
Acne, also called acne vulgaris, refers to a phenomenon in which papules or pustules form along the pores. Acne occurs on the face of males and females, especially in adolescence and adolescence, and there is a strong demand for their prevention and improvement. For this reason, many skin external preparations for preventing and improving acne, such as emulsions, creams, lotions, packs, cleaning agents, dispersions, ointments, external preparations and the like, are provided.
[0003]
In these external preparations for skin, anti-inflammatory agents such as glycyrrhizic acid, glycyrrhetinic acid and derivatives thereof, and bactericides such as sulfur and resorcin have been used as components for preventing or improving acne.
[0004]
[Problems to be solved by the invention]
However, these anti-inflammatory agents and fungicides are often not effective in preventing or improving acne, or are not capable of obtaining the desired medicinal effects due to deterioration in the preparation. Therefore, it has been desired to find a drug having an excellent effect of preventing and improving acne and to provide a skin external preparation for acne containing the same.
[0005]
[Means for Solving the Problems]
The present inventors have sought various factors related to acne and found that singlet oxygen is greatly involved in the development of acne. Further, if a singlet oxygen scavenger in an amount that provides a singlet oxygen scavenging capacity or more than a predetermined amount is added to the external preparation for skin, acne prevention and improvement effects can be remarkably improved, and further this singlet oxygen scavenger The present invention was completed by finding that a higher acne prevention and improvement effect can be obtained by combining drugs such as ultraviolet light inhibitors, whitening agents, anti-inflammatory agents, bactericides, and cell activators.
[0006]
That is, the present invention provides a skin external preparation for acne characterized by containing a singlet oxygen scavenger in an amount of 50 s -1 or more as a singlet oxygen scavenging ability.
[0007]
The present invention also includes the following components (A) and (B)
(A) providing acne skin external agent characterized in that it contains a 50s -1 or more and comprising an amount of singlet oxygen quencher (B) one or two or more ultraviolet inhibitor as singlet oxygen erasability Is.
[0008]
Furthermore, the present invention provides a component (C) for the acne skin external preparation described above.
(C) The present invention provides a skin external preparation for acne containing one or more kinds of agents selected from whitening agents, anti-inflammatory agents, bactericides, and cell activators.
[0009]
DETAILED DESCRIPTION OF THE INVENTION
The singlet oxygen scavenger used in the present invention is not particularly limited as long as it contains a compound capable of effectively scavenging singlet oxygen and causing no particular problem when added to a skin external preparation. can do. The compound acting as a singlet oxygen scavenger may be screened by any measurement method, but can be easily screened by using, for example, a singlet oxygen detector (Japanese Patent Laid-Open No. 7-159325). it can.
[0010]
In the present invention, specific examples of compounds used as an active ingredient of a singlet oxygen scavenger include rutin and its derivatives, quercetin, β-carotene, astaxanthin, zeaxanthin, vitamin E and its derivatives, and salts thereof, erythorbic acid Histidine, tryptophan, tyrosine, methionine, cystine, hypotaurine, thiotaurine, carrot extract, micaika extract, sunpens extract, melissa extract, yashajitsu extract, rahan fruit extract, tea extract, phospholipid and the like.
[0011]
The content of the singlet oxygen scavenger in the external preparation for acne of the present invention needs to be an amount that is 50 s -1 or more as its singlet oxygen scavenging ability. That is, each compound as an active ingredient of a singlet oxygen scavenger has a reaction rate constant per weight or mole, but the singlet oxygen scavenging ability obtained by multiplying this reaction rate constant and the blending concentration is 50 s −. It is important to make it 1 or more. In particular, when this value is 1000 s −1 or more, more excellent acne prevention and improvement effects can be obtained.
[0012]
The above singlet oxygen scavenger is an ingredient for preventing or improving acne, and it is formulated into various forms of bases used for normal skin external preparations according to conventional methods, and formulated into a skin external use for acne. An acne preparation can be obtained, but an acne skin external preparation having a further excellent effect can be obtained by further combining with an ultraviolet light inhibitor and other medicinal ingredients.
[0013]
In the present invention, as the ultraviolet ray inhibitor (component (B)) used in combination with the singlet oxygen scavenger (component (A)), paramethoxycinnamic acid-2-ethylhexyl, oxybenzone, 4-tert-butyl- Examples thereof include 4′-methoxydibenzoylmethane, titanium oxide, fine particle titanium oxide, and zinc oxide. Among these UV inhibitors, paramethoxycinnamate-2-ethylhexyl, titanium oxide, fine particle titanium oxide, and zinc oxide are particularly preferable.
[0014]
On the other hand, the other medicinal components (component (C)) are selected from whitening agents, anti-inflammatory agents, bactericides, and cell activators. Specific examples of medicinal agents are shown below. Things.
[0015]
(Whitening agent)
As the whitening agent, vitamin C and its derivatives and salts thereof, placenta extract, licorice extract, yokuinin extract, ougon extract, seaweed extract, juniper extract, sempukuka extract, grape extract, wheat extract , Tomato extract and the like.
[0016]
Among these whitening agents, vitamin C and its derivatives, their salts, and placental extracts are particularly preferable.
[0017]
(Anti-inflammatory agent)
Anti-inflammatory agents include glycyrrhizic acid, glycyrrhetinic acid and their derivatives and their salts, aloe extract, perilla extract, mugwort extract, chamomile extract, comfrey extract, gill extract, watercress extract, buckwheat An extract etc. are mentioned.
[0018]
Among these anti-inflammatory agents, particularly preferred are glycyrrhizic acid, glycyrrhetinic acid and derivatives thereof, and salts thereof.
[0019]
( Fungicide )
Examples of the disinfectant include sulfur, resorcin, salicylic acid, isopropylmethylphenol, benzalkonium chloride, hinokitiol, dokudami extract, and clara extract.
[0020]
Among these fungicides, particularly preferred are sulfur, salicylic acid, and isopropylmethylphenol.
[0021]
(Cell activator)
Cell activators include fermentative metabolism of vitamin A and its derivatives, citric acid, lactic acid, tartaric acid, malic acid, glycolic acid, succinic acid, serine, glutamic acid, hydroxyproline, theanine, pyrrolidone carboxylic acid, yeast, lactic acid bacteria and bifidobacteria Thing etc. are mentioned.
[0022]
Among these cell activators, vitamin A and its derivatives, citric acid, malic acid, lactic acid, serine, and pyrrolidone carboxylic acid are particularly preferable.
[0023]
In the external preparation for skin of the present invention, the blending amounts of the above-mentioned UV inhibitor of component (B) and the medicinal agent of component (C) are different depending on the type, but are preferably in the ranges shown below. Within this range, when combined with the singlet oxygen scavenger of component (A), it does not affect the temporal stability of the singlet oxygen scavenger of the preparation and component (A) in the preparation, and is higher. Acne prevention and improvement effects can be demonstrated.
[0024]
That is, the blending amount of the component (B) in the present invention is preferably 0.001 to 20% by mass (hereinafter simply referred to as “%”), more preferably 0.01 to 10%. If it is in this range, an excellent anti-ultraviolet effect is exhibited, and an external preparation for skin that exhibits excellent acne prevention and improvement effects can be obtained.
[0025]
On the other hand, the blending amount of the whitening agent in the component (C) of the present invention is preferably 0.0001 to 10%, more preferably 0.0001 to 5%. When a placenta extract and a plant extract are used as an extract, there is no problem as long as the dry solid content is within this range. If it is this range, the skin external preparation which shows the more excellent acne prevention and improvement effect will be obtained.
[0026]
Moreover, the compounding quantity of an anti-inflammatory agent among (C) component of this invention has the preferable range of 0.0001-5%, More preferably, it is the range of 0.00013%. When the plant extract is used as it is, there is no problem if it is in this range as the dry solid content. If it is this range, the outstanding anti-inflammatory effect will be seen and the skin external preparation which shows the outstanding acne prevention and improvement effect will be obtained.
[0027]
Further, the blending amount of the bactericide in the component (C) of the present invention is preferably in the range of 0.0001-5%, more preferably in the range of 0.00013%. When the plant extract is used as it is, there is no problem if it is in this range as the dry solid content. If it is this range, the outstanding bactericidal effect will be seen, and the skin external preparation which shows the acne prevention and improvement effect which was excellent will be obtained.
[0028]
Furthermore, the blending amount of the cell activator which is the component (C) of the present invention is preferably 0.0001 to 5%, more preferably 0.0001 to 3%. If it is this range, the skin roughening agent which the outstanding skin roughness improvement effect will express and the outstanding acne prevention and improvement effect is obtained is obtained.
[0029]
In producing the skin external preparation for acne of the present invention, (B) component UV protection agent and (C) medicinal agent (whitening agent, anti-inflammatory agent, bactericidal agent and cell activator) They can be used in combination, and a plurality of compounds or medicinal agents can be blended in each component. Furthermore, the whitening agent, the anti-inflammatory agent, the bactericidal agent and the cell activator which are the medicinal agents of the component (C) can also be used in combination of two or more by selecting a plurality of compounds from each.
[0030]
The topical skin preparation in which the component (B) and / or the component (C) is combined with the component (A) of the present invention is a base in various forms known as ordinary skin topical preparations according to conventional methods. It can mix | blend and prepare. In this case, the compounding amount of the component (A) is also required to be an amount of 50 s −1 or more as the singlet oxygen scavenging ability as described above.
[0031]
The form of acne skin external preparation thus obtained is not particularly limited, and for example, cosmetics such as emulsions, creams, lotions, packs, cleaning agents, makeup cosmetics, dispersions, ointments, and external medicines are used. be able to.
[0032]
And according to the form of the above-mentioned skin external preparation, in addition to the above essential ingredients, components usually used in skin external preparations such as cosmetics and pharmaceuticals, for example, purified water, lower alcohol, polyhydric alcohol, oil component, powder, surface activity Agents, thickeners, coloring materials, preservatives, humectants, fragrances, and the like can be used.
[0033]
[Action]
The present invention is based on the novel finding that singlet oxygen is greatly involved in the development of acne. That is, in the sebaceous glands that are the organs that produce sebum, acne bacteria ( Propioniobacterium acnes ) are inhabited, and acne bacteria produce porphyrins as metabolites and excrete out of the cells. Our study revealed that this porphyrin is excreted on the skin surface along with sebum secretion. When the porphyrin discharged on the skin surface is exposed to ultraviolet rays, singlet oxygen detectors developed by us (Japanese Patent Laid-Open No. 7-7 / 1990) indicate that singlet oxygen, which is a kind of active oxygen and is highly reactive, is generated. 159325).
[0034]
It is also clear that epidermal lipids on the skin surface are unexpectedly not peroxidized at all by UV irradiation alone, but are only peroxidized rapidly by the presence of singlet oxygen produced by this porphyrin. became. The lipid peroxide promotes hyperkeratinization of the epidermis, and the stratum corneum near the pores becomes harder and thicker. Therefore, it has been found for the first time that pores tend to clog and cause acne.
[0035]
By the way, since a representative epidermal lipid component that is peroxidized by singlet oxygen is squalene, in order to prevent peroxidation of squalene causing acne, a component that reacts with singlet oxygen more easily than squalene. Apply to the skin. And since the ease of reaction with a singlet oxygen of a certain compound is determined by the reaction rate constant and the blending concentration, the singlet oxygen scavenging ability in an actual skin external preparation is required in consideration of both.
[0036]
Based on such knowledge, the present invention is completed as a singlet oxygen scavenger having a singlet oxygen scavenging ability of a certain number or more suppresses peroxidation of squalene on the skin and is effective in preventing and improving acne. It is a thing.
[0037]
In addition, since the source of singlet oxygen is the excitation of porphyrin by ultraviolet rays, protecting the ultraviolet rays that are the cause is effective in preventing singlet oxygen damage and is very effective in preventing and improving acne. They found it to be effective.
[0038]
【Example】
EXAMPLES Next, although an Example and a test example are given and this invention is demonstrated further in detail, this invention is not restrict | limited at all to these.
[0039]
Test example 1
Measurement of singlet oxygen scavenging ability:
Using the singlet oxygen detector disclosed in JP-A-7-159325, the singlet oxygen elimination rate constant was measured for the test agent * shown in Table 1 as follows. That is, Rose Bengal 100 μM solution was used as a control sample, and this was circulated at a rate of 20 mL / min in the flow cell. This cell was irradiated with laser light having a UVA wavelength. Since the emission spectrum generated by this irradiation has a peak derived from singlet oxygen at 1268 nm, the emission intensity of this control sample is Io. Next, the test drug was added to the control sample and the same operation was performed, and the obtained luminescence intensity was defined as Is. Plotting the ratio Io / Is of the luminescence intensity against the compound concentration (Cs) of the test agent, the following Stern-Volmer equation (1),
Io / Is = 1 + kq · τ · Cs (1)
τ: Lifetime of singlet oxygen (a constant that varies depending on the solvent)
Cs: The singlet oxygen elimination rate constant (kq) was determined from the blending concentration of the test drug.
The actual singlet oxygen scavenging ability is expressed by equation (2),
Is obtained by multiplying the singlet oxygen elimination rate constant by the actual blending concentration. In addition, the density | concentration (Cs) of the test chemical | medical agent was prepared by solid substance concentration (g * L <-1 >).
[0040]
* Among the test drugs, plant extracts were prepared as follows. First, each herbal medicine is dried and chopped. 100 parts by weight of 50% ethyl alcohol aqueous solution was added to 10 parts by weight of this chopped crude drug, extracted for 3 days with occasional stirring at room temperature, and then filtered to obtain each extract.
[0041]
Table 1 shows the results of evaluating the singlet oxygen scavenging ability of each test drug. The singlet oxygen scavenging ability was evaluated in the following three stages.
[0042]
[0043]
(Result)
[Table 1]
[0044]
As is apparent from the results in Table 1, each of the test drugs A1 to A24 was found to have a high singlet oxygen scavenging ability, and the singlet generated from porphyrin produced by Acne bacteria was added to the skin external preparation containing these. It was judged that there was an effect of preventing and improving acne due to oxygen.
[0045]
Example 1
Milk liquid:
An emulsion was prepared by the following composition and the following production method, and the acne prevention and improvement effects were examined. The results are shown in Table 2.
[0046]
(Production method)
A. Components (1) to (6) are heated and mixed and kept at 70 ° C.
B. A part of components (9) and (11) are heated and mixed and kept at 70 ° C.
C. Add A to B, mix, and uniformly emulsify.
(7), (8), (12) and (13) dissolved in the remainder of (11) after cooling D. C were added and mixed uniformly to obtain an emulsion.
[0047]
( Test method )
A panel of 15 females aged 22 to 40 years per test milk was applied to the face with an appropriate amount of test milk after washing the face twice daily in the morning and night. The coating was carried out for 12 weeks, and the effectiveness of the acne improving effect by the coating was judged by the following three ranks, and evaluated according to the following evaluation criteria.
[0048]
(Effectiveness rank)
Effective ... ... Acne is difficult to make. Acne disappeared.
Slightly effective…… Acne is a little difficult to do. Acne is less noticeable.
Ineffective… No change from before use.
[0049]
[0050]
(Result)
[Table 2]
[0051]
As shown in Table 2, topical skin preparations containing singlet oxygen scavengers with a singlet oxygen scavenging ability of 50 s -1 or more in Table 1 can prevent or improve acne by applying them to the skin. It has become clear that the skin can be beautiful. In particular, preferably the skin external preparation containing a combination of the singlet oxygen scavenger so that the above 1000 s -1, the effect was excellent.
[0052]
Example 2
Milk liquid:
Agents such as singlet oxygen scavengers, UV inhibitors, whitening agents, anti-inflammatory agents, bactericides, and cell activators as shown in Table 3 are added to the following basic composition, and an emulsion is prepared by the following method. Then, the skin beautifying effect was examined. The results are also shown in Table 3. The basic composition and the blending amounts shown in Table 3 are blending amounts in the final product emulsion.
[0053]
[0054]
(Composition and results)
[Table 3]
[0055]
(Production method)
A. Components (1) to (6) are heated and mixed and kept at 70 ° C.
B. A part of components (9) and (11) are heated and mixed and kept at 70 ° C.
C. Add A to B, mix, and uniformly emulsify.
D. C was dissolved in the remainder of (11) after cooling (7), (8), (12) and the components of (13) to (40) in Table 3 were added to (10) and mixed uniformly. To obtain an emulsion.
[0056]
( Test method )
The test milk was evaluated in the same manner as in Example 1.
[0057]
As shown in the results of Table 3, a skin external preparation containing a singlet oxygen scavenger having a singlet oxygen scavenging ability of 50 s -1 or more is used as an anti-UV agent, whitening agent, anti-inflammatory agent, bactericidal agent. When applied to the skin in combination with an agent and cell activator, it exhibits an even better prevention and improvement effect of acne than when an external preparation containing a singlet oxygen scavenger alone is applied, and is transparent It became clear that it was beautiful skin.
[0058]
[0059]
(Production method)
A. Components (3), (4), (9) and (10) are mixed and dissolved.
B. Components (1), (2), (5) to (8) and (11) are mixed and dissolved.
C. A and B were mixed and uniformed to obtain a skin lotion.
[0060]
[0061]
(Production method)
A. Ingredients (1)-(6) and (11) are mixed and heated to keep at 70 ° C.
B. Heat component (13) and maintain at 70 ° C.
C. B was added to A, (7) to (10) and (12) were mixed, and then cooled to obtain a cream.
[0062]
The lotion obtained in Example 3 and the cream obtained in Example 4 are both excellent in stability over time, and are applied to the skin to prevent and ameliorate acne and make the skin beautiful and transparent. It was.
[0063]
[0064]
(Production method)
A. A part of components (3), (4) and (8) are heated and mixed and kept at 75 ° C.
B. Ingredients (1) and (2) are heated and mixed and kept at 75 ° C.
C. Gradually add A to B.
(5)-(7) dissolved in the remainder of (8) was added while cooling C. C to obtain an ointment.
[0065]
The ointment obtained in Example 5 was excellent in stability over time, and applied to the skin to prevent acne and to make the skin beautiful and transparent.
[0066]
[0067]
(Production method)
A. Ingredients (1), (3), (4) and (10) are mixed, heated to 70 ° C. and stirred.
B. Mix components (2) and (8).
C. The above B was added to the above A, mixed, and then cooled to uniformly disperse (5) to (7) and (9) to obtain a pack.
[0068]
The pack of Example 6 was excellent in stability over time, and applied to the skin to prevent acne and to make the skin beautiful and transparent.
[0069]
[0070]
(Production method)
A. The components (1) to (5) are mixed and dissolved.
B. Add components (10) to (15) to A, mix uniformly, and maintain at 70 ° C.
C. Components (6) to (9) are uniformly dissolved and maintained at 70 ° C.
D. Add C to B and emulsify uniformly.
After cooling E. D, components (16) to (19) were added to obtain a liquid foundation.
[0071]
The liquid foundation obtained in Example 7 was excellent in stability with time and applied to the skin to prevent acne.
[0072]
【The invention's effect】
As described above, the external preparation for skin of the present invention containing a singlet oxygen scavenger having a singlet oxygen scavenging capacity of a certain level or more has a singlet oxygen generated from porphyrin produced by acne bacteria by the singlet oxygen scavenging capacity. It is effective in eliminating and improving acne.
[0073]
Furthermore, by combining the above singlet oxygen scavenger with ultraviolet absorbers, bactericides, anti-inflammatory agents, whitening agents, cell activators, it has a high preventive and ameliorating effect against acne, and acne scar pigmentation It can be used as a skin external preparation effective for improvement and the like.
more than
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000098285A JP4070935B2 (en) | 2000-03-31 | 2000-03-31 | Acne skin external preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000098285A JP4070935B2 (en) | 2000-03-31 | 2000-03-31 | Acne skin external preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001288035A JP2001288035A (en) | 2001-10-16 |
| JP4070935B2 true JP4070935B2 (en) | 2008-04-02 |
Family
ID=18612786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000098285A Expired - Lifetime JP4070935B2 (en) | 2000-03-31 | 2000-03-31 | Acne skin external preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4070935B2 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004161641A (en) * | 2002-11-12 | 2004-06-10 | Nonogawa Shoji Kk | Cosmetic |
| JP4050635B2 (en) * | 2003-03-03 | 2008-02-20 | 株式会社ナリス化粧品 | Skin preparation |
| JP2005053785A (en) * | 2003-05-20 | 2005-03-03 | Nippon Menaade Keshohin Kk | External preparation |
| FR2857266B1 (en) * | 2003-07-07 | 2007-09-21 | Jean Noel Thorel | COMPOSITION FOR DERMATOLOGICAL AND / OR COSMETIC USE, COMPRISING AS ACTIVE INGREDIENT AT LEAST ONE LIPOPHILIC ANTIOXIDANT |
| CA2588905A1 (en) * | 2004-11-22 | 2006-06-15 | Nu-Tein Co., Inc. | Topical skin patch containing xanthophylls |
| JP4766907B2 (en) * | 2005-04-13 | 2011-09-07 | 株式会社ノエビア | Topical skin preparation |
| JP5220415B2 (en) * | 2005-09-06 | 2013-06-26 | 株式会社明治 | Amino acid composition for preventing or treating senile anemia |
| JP2008120781A (en) * | 2006-11-13 | 2008-05-29 | Saraya Kk | External preparation for skin containing momordica grosvenori glycoside |
| EP2318011A4 (en) * | 2008-07-17 | 2011-09-14 | Georgia Levis | Methods and materials for the treatment of acne |
| JP5674262B2 (en) * | 2008-08-08 | 2015-02-25 | 花王株式会社 | Hair dye composition |
| JP2010202617A (en) * | 2009-03-05 | 2010-09-16 | Kose Corp | Singlet oxygen eliminator, and skin care preparation and cosmetic containing the same |
| US20120135093A1 (en) * | 2009-07-14 | 2012-05-31 | Soonchunhyand University Industry Academy Cooperation Foundation | Soap composition for treating acne containing absolute ginseng essential oil |
| DE102009044974A1 (en) * | 2009-07-23 | 2011-01-27 | Henkel Ag & Co. Kgaa | Use of dihydroquercetin and at least one amino acid to positively influence the natural pigmentation process |
| KR101308507B1 (en) * | 2011-07-07 | 2013-09-17 | (주)비알뷰티플레볼루션 | Acne therapeutics and sebum secernent inhibitor which comprise tryptophan, and kits for photodynamic therapy containing the same |
| JP2013155158A (en) * | 2012-01-31 | 2013-08-15 | Increase Kenkyusho:Kk | Antimicrobial agent composition and method for producing the same |
| JP2019129789A (en) * | 2018-02-01 | 2019-08-08 | 株式会社ノエビア | Anti-acne food, hair quality improving food or makeup applicability improving food |
| JP7533892B2 (en) * | 2021-01-04 | 2024-08-14 | 国立研究開発法人国際農林水産業研究センター | Antioxidant and its manufacturing method |
| GB202113755D0 (en) * | 2021-09-27 | 2021-11-10 | Givaudan Sa | Skin protection |
| JP2024078511A (en) * | 2022-11-30 | 2024-06-11 | 長谷川香料株式会社 | Skin improvement agent |
| JP2024034621A (en) * | 2022-09-01 | 2024-03-13 | 長谷川香料株式会社 | Pore improver |
| CN116492238B (en) * | 2023-04-23 | 2024-07-30 | 广州集妍化妆品科技有限公司 | Composition for preventing and treating acne and its application |
-
2000
- 2000-03-31 JP JP2000098285A patent/JP4070935B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001288035A (en) | 2001-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4070935B2 (en) | Acne skin external preparation | |
| CN102387786B (en) | Antifungal pharmaceutical composition | |
| JP2000095663A (en) | Agent for external use containing plant extract | |
| JPH07233046A (en) | External preparation | |
| JP4004182B2 (en) | Emulsified composition | |
| WO2003015739A1 (en) | Dual compartment packaged cosmetic composition | |
| WO2001085156A1 (en) | Dermal compositions containing coenzyme q as the active ingredient | |
| US20080319060A1 (en) | Composition containing vitamin c | |
| JPH09157153A (en) | Preparation for external use for skin | |
| JPH05124925A (en) | External preparation with melanin production-inhibitory activity | |
| JP2010202617A (en) | Singlet oxygen eliminator, and skin care preparation and cosmetic containing the same | |
| JP7328957B2 (en) | External composition containing ascorbic acid and/or its salt | |
| JP6757130B2 (en) | A composition having an azulene compound, and a discoloration inhibitor and a discoloration prevention method for the azulene compound. | |
| JPH06172147A (en) | Composition for local application for protecting from ultraviolet ray | |
| JP2003530420A (en) | Use of alcohol dehydrogenase inhibitors in the cosmetic treatment of keratin substances | |
| JP4926354B2 (en) | Topical skin preparation | |
| JPS63183518A (en) | hair composition | |
| JP2000281555A (en) | Skin preparation for external use | |
| JP2006315957A (en) | Singlet oxygen scavenger and external preparation for skin using the same | |
| JP2010235483A (en) | Singlet oxygen scavenger and skin external preparation and cosmetic containing the same | |
| JPS60116616A (en) | Cosmetic | |
| JPH04120008A (en) | New beautifying cosmetic | |
| JPS6391312A (en) | Cosmetic | |
| JPS5936606A (en) | Cosmetic | |
| KR20040057413A (en) | Cosmetic Product containing Ascorbic Acid-2-Glucoside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050819 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061024 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070529 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070727 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070727 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071225 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080116 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4070935 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110125 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140125 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |